NR4A1 and cancer: In the present study, based on the results illustrated in Figure 1 demonstrating that TTD is the most potent inhibitor of nuclear NR4A1 among the structural derivatives of FCN, we hypothesized that TTD may be an NR4A1 antagonist to inhibit cancer cell growth in both cell culture and in vivo models.